Related Experiment Video
Updated: Jul 3, 2025
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
Updates on respiratory syncytial virus prophylaxis: the past, present and future
Anne Coates1, Christy Sadreameli
1Tufts University School of Medicine, Portland, Maine, USA.
Insights
Human respiratory syncytial virus (RSV) causes severe respiratory infections, particularly in infants. Recent advancements offer new preventive options, but challenges remain in cost, insurance, and equitable distribution of these therapies.
Area of Science:
- Pediatric Infectious Diseases
- Vaccinology
- Public Health
Background:
- Human respiratory syncytial virus (RSV) is a leading cause of acute respiratory infection globally, especially in infants and young children.
- While many cases present as mild cold-like symptoms, a significant number of infants develop severe lower respiratory tract disease, including pneumonia and bronchiolitis, necessitating emergency care or hospitalization.
- Hospitalization rates for RSV in the United States have increased, with a notable proportion of severe cases occurring in previously healthy infants, not just those with pre-existing conditions.
Purpose of the Study:
- To review the current landscape of respiratory syncytial virus (RSV) vaccine development and prophylaxis.
- To discuss the spectrum of available RSV preventive interventions.
- To highlight challenges related to the cost, insurance coverage, and equitable distribution of RSV therapies.
Main Methods:
- Literature review of recent studies on RSV vaccine development.
- Analysis of current RSV prophylaxis strategies and their accessibility.
- Examination of economic and logistical barriers to widespread RSV prevention.
Main Results:
- RSV remains a significant public health concern, particularly for infants, with rising hospitalization rates.
- While new preventive interventions are emerging, access is often limited by cost and insurance coverage.
- Equitable distribution of RSV prophylaxis presents a substantial challenge.
Conclusions:
- Preventive interventions against RSV are critical due to the virus's widespread impact on infants.
- Addressing financial and logistical barriers is essential for ensuring equitable access to new RSV therapies.
- Continued research and policy development are needed to combat RSV effectively.
Purpose Of Review:
Human respiratory syncytial virus (RSV) causes acute respiratory infection in individuals of all age groups. It is the most common pathogen identified in infants and young children with acute lower respiratory infection. Although most infants and young children experience mild, cold-like symptoms, some infants develop severe lower respiratory tract disease such as pneumonia and bronchiolitis that may result in an emergency department visit or hospitalization.
Recent Findings:
In the United States, hospitalization rates have risen during the last decades, and while premature infants with chronic lung disease and congenital heart disease are at increased risk for severe presentations, the majority of hospitalizations occur in previously healthy infants. Until recently, RSV prophylaxis was only available for former preterm infants and those with certain underlying medical conditions.
Summary:
The need for preventive interventions against RSV is crucial. This paper will provide a review of the vaccine development, the spectrum of RSV prophylaxis, current challenges associated with the cost, insurance coverage and equitable distribution of targeted therapies.
More Related Videos
Related Concept Videos
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:31Common Respiratory Disorders
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:21Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
01:30Asthma-IV: Nursing Management
First, in...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...